JPWO2023146987A5 - - Google Patents

Info

Publication number
JPWO2023146987A5
JPWO2023146987A5 JP2024544444A JP2024544444A JPWO2023146987A5 JP WO2023146987 A5 JPWO2023146987 A5 JP WO2023146987A5 JP 2024544444 A JP2024544444 A JP 2024544444A JP 2024544444 A JP2024544444 A JP 2024544444A JP WO2023146987 A5 JPWO2023146987 A5 JP WO2023146987A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503969A (ja
JP2025503969A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/011654 external-priority patent/WO2023146987A1/en
Publication of JP2025503969A publication Critical patent/JP2025503969A/ja
Publication of JPWO2023146987A5 publication Critical patent/JPWO2023146987A5/ja
Publication of JP2025503969A5 publication Critical patent/JP2025503969A5/ja
Pending legal-status Critical Current

Links

JP2024544444A 2022-01-26 2023-01-26 化合物及び使用方法 Pending JP2025503969A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263303409P 2022-01-26 2022-01-26
US63/303,409 2022-01-26
US202263435210P 2022-12-23 2022-12-23
US63/435,210 2022-12-23
PCT/US2023/011654 WO2023146987A1 (en) 2022-01-26 2023-01-26 Compounds and methods of use

Publications (3)

Publication Number Publication Date
JP2025503969A JP2025503969A (ja) 2025-02-06
JPWO2023146987A5 true JPWO2023146987A5 (https=) 2026-02-04
JP2025503969A5 JP2025503969A5 (https=) 2026-02-04

Family

ID=85328599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544444A Pending JP2025503969A (ja) 2022-01-26 2023-01-26 化合物及び使用方法

Country Status (10)

Country Link
US (1) US20250136594A1 (https=)
EP (1) EP4469438A1 (https=)
JP (1) JP2025503969A (https=)
KR (1) KR20240153335A (https=)
AU (1) AU2023213736A1 (https=)
CA (1) CA3243127A1 (https=)
IL (1) IL314320A (https=)
MX (1) MX2024009177A (https=)
TW (1) TW202339736A (https=)
WO (1) WO2023146987A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025525104A (ja) * 2022-07-28 2025-08-01 ベイジン アースワイズ テクノロジー カンパニー リミテッド Prmt5阻害剤
WO2024104244A1 (zh) * 2022-11-15 2024-05-23 四川科伦博泰生物医药股份有限公司 草酸酰胺化合物、包含其的药物组合物及其制备方法和用途
CN120019044A (zh) * 2022-12-22 2025-05-16 成都苑东生物制药股份有限公司 一种取代草酰胺类衍生物、其制备方法及用途
JP2026504087A (ja) * 2023-01-17 2026-02-03 スジョウ・プヘ・バイオファーマ・カンパニー・リミテッド Prmt5-mta阻害剤
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN118290386B (zh) * 2024-04-02 2025-06-20 国科大杭州高等研究院 7-羟基黄酮类化合物及其制备方法和应用
WO2025217297A1 (en) 2024-04-09 2025-10-16 Tango Therapeutics, Inc. Prmt5 inhibitors for use in methods of treating mta-accumulating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US11077101B1 (en) * 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
WO2021004547A1 (en) * 2019-07-11 2021-01-14 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of hpk1
CN116568677A (zh) * 2020-07-31 2023-08-08 探戈医药股份有限公司 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物

Similar Documents

Publication Publication Date Title
AU2007337886B2 (en) Bicyclic heterocyclic compounds as FGFR inhibitors
CA3034705C (en) Inhibitors of cellular metabolic processes
ES2908042T3 (es) Heteroarilos y usos de los mismos
CN101678014B (zh) 杂环激酶调节剂
JP5881704B2 (ja) Namptの阻害のための新規な化合物及び組成物
JP2011510995A5 (https=)
US10786492B2 (en) Formylated N-heterocyclic derivatives as FGFR4 inhibitors
CN102753547A (zh) 三唑并吡啶衍生物
CN108366992A (zh) 蛋白水解靶向嵌合体化合物及其制备和应用方法
CN108348523A (zh) 包含pi3k抑制剂和hdac抑制剂的组合物
BR112021007213A2 (pt) derivados de quinolina como inibidores de integrina alfa4beta7
RU2018138471A (ru) Гетероциклические соединения в качестве ингибиторов киназы RET
HRP20170349T1 (hr) Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže
AU2013225533A1 (en) Amido spirocyclic amide and sulfonamide derivatives
JP2005320351A5 (https=)
CN103421005A (zh) 具有抗肿瘤活性的乙炔衍生物
CN104276993B (zh) 吲哚衍生物及其在药物上的应用
AU2015402778B2 (en) Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
CN109627239A (zh) 成纤维细胞生长因子受体的抑制剂
CN103429591A (zh) 在治疗过度增殖性病症中用作mps-1和tkk抑制剂的6-取代的咪唑并吡嗪
RU2014118677A (ru) Ингибиторы киназ типа polo
CA3240888A1 (en) Tyk2 inhibitors and compositions and methods thereof
CN117653636B (zh) 含稠合双环类化合物的抗癌药及该化合物的制药用途
JPWO2023146987A5 (https=)
CN103080109A (zh) 氘代杂环化合物激酶抑制剂